In EGFR-mutant lung cancer, IL-8 is upregulated in gefitinib-resistant cells, and high plasma IL-8 levels are correlated with shorter progression-free survival (PFS) in patients treated with EGFR-TKIs [179]. This evidence concerns the gene EGFR and lung carcinoma.